Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study (Q63571185)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study |
clinical trial |
Statements
A Randomized, Double -Blind, Placebo-Controlled, Phase 1, Ascending Oral Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-041 in Healthy Subjects and Subjects With Stable Schizophrenia and a Randomized Open-Label, Single Dose, Parallel Design to Evaluate the Relative Bioavailability and Effect of Food on the Pharmacokinetics of TAK-041 Tablet Formulation in Healthy Subjects (English)
0 references
9 May 2016
0 references
29 August 2019
0 references
114
0 references
18 year
0 references
55 year
0 references